A narrative review of genetic factors affecting fluoropyrimidine toxicity
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Objective: Our objective is to document progress in developing personalized therapy with fluoropyrimidine drugs (FPs) to improve outcomes for cancer patients and to identify areas requiring further investigation. Background: FPs including 5-fluorouracil (5-FU), are among the most widely used drugs for treating colorectal cancer (CRC) and other gastrointestinal (GI) malignancies. While FPs confer a survival benefit for CRC patients, serious systemic toxicities, including neutropenia, occur in ~30% of patients with lethality in 0.5−1% of patients. While serious systemic toxicities may occur in any patient, patients with polymorphisms in DPYD , which encodes the rate-limiting enzyme for pyrimidine degradation are at very high risk. Other genetic factors affecting risk for 5-FU toxicity, including miR-27a, are under investigation. Methods: Literature used to inform the text of this article was selected from PubMed.gov from the National Library of Medicine while regulatory documents were identified via Google search. Conclusions: Clinical studies to date have validated four DPYD polymorphisms ( DPYD *2A, DPYD *13, c.2846A>T, HapB3) associated with serious toxicities in patients treated with 5-FU. Genetic screening for these is being implemented in the Netherlands and the UK and has been shown to be a cost-effective way to improve outcomes. Factors other than DPYD polymorphisms (e.g., miR-27a, TYMS , ENOSF1, p53) also affect 5-FU toxicity. Functional testing for deficient pyrimidine catabolism {defined as [U] >16 ng/mL or [UH2]:[U] <10} is being implemented in France and has demonstrated utility in identifying patients with elevated risk for 5-FU toxicity. Therapeutic drug monitoring (TDM) from plasma levels of 5-FU during first cycle treatment also is being used to improve outcomes and pharmacokinetic-based dosing is being used to increase the percent of patients within optimal area under the curve (AUC) (18–28 mg*h/L) values. Patients maintained in the optimal AUC range experienced significantly reduced systemic toxicities. As understanding the genetic basis for increased risk of 5-FU toxicity becomes more refined, the development of functional-based methods to optimize treatment is likely to become more widespread.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adjuvant chemotherapy is administered to reduce the risk for disease recurrence in CRC patients undergoing surgical resection for primary colon cancer with curative intent [131].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“While the anti-cancer activities of FPs result primarily from conversion to FdUMP and inhibition of TS (2,37), up to 90% of 5-FU is degraded (38).”
BackgroundFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 2×
“However, its use was associated with higher incidence of toxic effects (23), demonstrating the need to better understand and manage toxicities related to FP use.”
BackgroundSargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623 · cited 4×
“The mechanistic basis for lack of efficacy of FPs in dMMR CRC is not clearly understood, however MSI is also associated with elevated thymidylate synthase (TS) (20,21), which is the molecular target of FP chemotherapy (2).”
BackgroundInfluentialGill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021 · cited 1×
“An intergroup analysis reported a statistically significant improvement in 5-year DFS for stage II patients treated with chemotherapy, but improvement in overall survival was not statically significant (12).”
BackgroundAmstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.911 · Cited by 694 · cited 1×
“Although >160 SNPs in DPYD have been reported (49) as outlined by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (6), relatively few are both highly prevalent and have a substantial effect on DPD activity to justify pre-emptive screening.”
BackgroundSargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666 · cited 1×
“Follow-up analysis of long-term outcomes demonstrated 5-FU chemotherapy was associated with a 5% absolute improvement in survival at 8 years (13).”
Background(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Frederix, G. W. J., Kienhuis, E., Creemers, G.-J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30686-7 · Cited by 444 · cited 3×
“The recommendations adopted in the UK parallel results from clinical studies in the Netherlands (58) and other countries that demonstrated prospective screening for clinically-relevant DPYD variants was feasible, and that DPYD genotype to guide dose improved outcomes.”
ResultInfluential5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433 · cited 1×
“Cardiotoxicity, while relatively rare, is a potentially lethal occurrence with high risk for long-term morbidity and mortality (28), and its risk with 5-FU is second only to anthracyclines (29).”
BackgroundMicrosatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418 · cited 2×
“Gatalica Z, Vranic S, Xiu J, et al. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.”
BackgroundPostoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-011
Wolmark, N., Fisher, B., Rockette, H., Redmond, C., Wickerham, D. L., Fisher, E. R., Jones, J., Glass, A., Lerner, H., Lawrence, W., et al. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.1.30 · Cited by 400 · cited 1×
“For patients with stage III colon cancer the survival benefit of FP-based chemotherapy regimens outweighs potential risks for serious toxicities and the optimization of FP-based chemotherapy has evolved since initial report of therapeutic benefit in 1988 (17).”
BackgroundStanding the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., Largiadèr, C. R., Jennings, B. A., Marinaki, A. M., Sanderson, J. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00286-7 · Cited by 381 · cited 1×
“The clinical relevance of these four SNPs for increased risk of serious toxicities resulting from FP treatment was established by meta-analysis of multiple clinical studies (53).”
BackgroundBöckelman, C., Engelmann, B. E., Kaprio, T., Hansen, T. F., & Glimelius, B. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.975839 · Cited by 367 · cited 1×
“In stage II disease 5-year survival is 82–88%, and use of adjuvant chemotherapy remains controversial (11).”
BackgroundUpfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., Smits, P. H., Rosing, H., Mandigers, C. M. P. W., Soesan, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1325 · Cited by 360 · cited 1×
“Importantly, the data also support that prospective DPYD screening not only decreases the incidence of serious toxicities, but reduces overall cost of treatment by an amount that is greater than the cost of screening (59).”
BackgroundKuilenburg, A. B. P., Haasjes, J., Richel, D. J., Zoetekouw, L., van LENTHE, H., ABREU, R. A. D., Maring, J. G., Vreken, P., & Gennip, A. H. (2000) · PubMed · Cited by 359
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
Milano, G., Etienne, M. C., Pierrefite, V, Barberi-Heyob, M., Deporte-Fety, R., & Renée, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690098 · Cited by 275 · cited 1×
“Since only 39–61% of patients with serious 5-FU toxicities display polymorphisms associated with reduced DPD activity (41,65) and <20% of patients that experience serious FP-related toxicities are identified by genotyping DPYD (34) other factors must contribute to 5-FU toxicity.”
BackgroundNoordhuis, P., Holwerda, U., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., Pinedo, H. M., & Peters, G. J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh264 · Cited by 264 · cited 1×
“, FUTP) are produced at much higher levels than the corresponding deoxyribonucleotides by ~10:1 ratio (76).”
BackgroundLunenburg, C. A. T. C., van der Wouden, C. H., Nijenhuis, M., Crommentuijn-van Rhenen, M. H., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder, H., Rongen, G. A., van Schaik, R. H. N., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0540-0 · Cited by 242 · cited 3×
“The Dutch Pharmacogenetics Working Group (DPWG) identified four DPYD variants for which sufficient evidence for reduced/complete DPD dysfunction (50) and the UK chemotherapy board (51) also considers these same four to have serious clinical impact affecting FP toxicity and since 2020 recommends pre-treatment pharmacog…”
BackgroundInfluentialMorel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., & Gamelin, E. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0327 · Cited by 236 · cited 1×
“Neutropenia is the most common toxicity associated with DPD deficiency with one study finding stage IV neutropenia occurring in 55% of patients with decreased DPD activity while the rate in patients with normal DPD activity was only 13% (55) and similar differential toxicity was found in other studies (56).”
ResultTherapeutic drug monitoring of 5-fluorouracil
Lee, J. J., Beumer, J. H., & Chu, E. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3054-2 · Cited by 229 · cited 2×
“For these reasons, approaches to TDM are being implemented to adjust 5-FU dosing for optimal therapeutic response (72).”
BackgroundMethodJohnson, M. R., Hageboutros, A., Wang, K., High, L. B., Smith, J. B., & Diasio, R. B. (1999) · PubMed · Cited by 225
Gamelin, E., Boisdron-Celle, M., Guérin-Meyer, V., Delva, R., Lortholary, A., Genevieve, F., Larra, F., Ifrah, N., & Robert, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1105 · Cited by 209
Pritchard, D. M., Watson, A. J. M., Potten, C. S., Jackman, A. L., & Hickman, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1795 · Cited by 198
Osterman, E., & Glimelius, B. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001158 · Cited by 192 · cited 2×
“An intergroup analysis reported a statistically significant improvement in 5-year DFS for stage II patients treated with chemotherapy, but improvement in overall survival was not statically significant (12).”
BackgroundMattison, L. K., Fourie, J., Desmond, R. A., Modak, A., Saif, M. W., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0747 · Cited by 174 · cited 1×
“Deficiencies in DPD activity occur in an estimated 3–8% of patients (34,41), and certain populations such as individuals of African descent, are at especially high risk to drug-induced toxicities due to variability in drug metabolism (42) while in Asian populations a distinct spectrum of polymorphisms affecting DPD ac…”
BackgroundEarly stage colon cancer: Current treatment standards, evolving paradigms, and future directions
Chakrabarti, S., Peterson, C. Y., Sriram, D., & Mahipal, A. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i8.808 · Cited by 174 · cited 2×
“or with regional lymph node involvement (stage III), surgery with curative intent is the preferred option, and adjuvant chemotherapy may be administered to reduce risk for disease recurrence (9).”
BackgroundEzzeldin, H., & Diasio, R. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.n.018 · Cited by 169 · cited 1×
“For example, the *2A (rs3918290) locus alters a splice recognition sequence leading to a 165 base pair deletion and expression of an inactive DPD protein (60).”
BackgroundManagement of cytotoxic chemotherapy-induced hand-foot syndrome
Kwakman, J. J. M., Elshot, Y. S., Punt, C. J. A., & Koopman, M. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.442 · Cited by 155 · cited 1×
“Dermatological toxicities, such as hand-foot syndrome, are common and generally occur later in treatment (25).”
BackgroundJohnson, M. R., & Diasio, R. B. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00011-x · Cited by 151 · cited 2×
“Deficiencies in DPD activity occur in an estimated 3–8% of patients (34,41), and certain populations such as individuals of African descent, are at especially high risk to drug-induced toxicities due to variability in drug metabolism (42) while in Asian populations a distinct spectrum of polymorphisms affecting DPD ac…”
BackgroundMeulendijks, D., Henricks, L. M., Jacobs, B., Aliev, A., Deenen, M. J., de Vries, N., Rosing, H., van Werkhoven, E. D., de Boer, A., Beijnen, J. H., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.94 · Cited by 145 · cited 1×
“(67), conducted testing in 550 patients and elevated plasma uracil concentration was significantly associated with global severe toxicity (P=0.”
BackgroundGatalica, Z., Vranic, S., Xiu, J., Swensen, J., & Reddy, S. (2016) · Familial Cancer · doi:10.1007/s10689-016-9884-6 · Cited by 141 · cited 1×
“The mechanistic basis for lack of efficacy of FPs in dMMR CRC is not clearly understood, however MSI is also associated with elevated thymidylate synthase (TS) (20,21), which is the molecular target of FP chemotherapy (2).”
BackgroundLunenburg, C. A. T. C., Henricks, L. M., Guchelaar, H., Swen, J. J., Deenen, M. J., Schellens, J. H. M., & Gelderblom, H. A. J. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.008 · Cited by 139 · cited 1×
“Collectively these studies established that dose adjustments based on prospective DPYD genotyping decreased toxicity while maintaining efficacy (52).”
BackgroundDihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Diasio, R. B., & Johnson, M. R. (1999) · PubMed · Cited by 113
Toffoli, G., Giodini, L., Buonadonna, A., Berretta, M., Paoli, A. D., Scalone, S., Miolo, G., Mini, E., Nobili, S., Lonardi, S., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29654 · Cited by 103 · cited 1×
“Although >160 SNPs in DPYD have been reported (49) as outlined by the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (6), relatively few are both highly prevalent and have a substantial effect on DPD activity to justify pre-emptive screening.”
BackgroundMeulendijks, D., Cats, A., Beijnen, J. H., & Schellens, J. H. M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.002 · Cited by 102 · cited 3×
“Deficiencies in DPD activity occur in an estimated 3–8% of patients (34,41), and certain populations such as individuals of African descent, are at especially high risk to drug-induced toxicities due to variability in drug metabolism (42) while in Asian populations a distinct spectrum of polymorphisms affecting DPD ac…”
BackgroundThe role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio, R. B. (1998) · PubMed · Cited by 96
5-FU induced cardiotoxicity: case series and review of the literature
Yuan, C., Parekh, H. D., Allegra, C. J., George, T. J., & Starr, J. S. (2019) · Cardio-Oncology · doi:10.1186/s40959-019-0048-3 · Cited by 95 · cited 1×
“Cardiotoxicity, while relatively rare, is a potentially lethal occurrence with high risk for long-term morbidity and mortality (28), and its risk with 5-FU is second only to anthracyclines (29).”
BackgroundOffer, S. M., Butterfield, G. L., Jerde, C. R., Fossum, C. C., Wegner, N. J., & Diasio, R. B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0878 · Cited by 92 · cited 2×
“Although deficiency in DPD activity in most individuals is considered to result from polymorphisms in DPYD affecting enzyme expression and function, other causes, such as variability in miR-27a regulation of DPYD have been identified (44).”
BackgroundLyons, L., ELBeltagy, M., Bennett, G., & Wigmore, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030010 · Cited by 90 · cited 1×
“5-FU crosses the blood-brain barrier and its use has been associated with cognitive impairment (30).”
BackgroundChemotherapy for Stage II Colon Cancer
Varghese, A. (2015) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0035-1564430 · Cited by 82 · cited 1×
“However, risks associated with FP-based treatment are real and potentially lethal, and for patients with stage II disease the potential risk-reducing benefits of FP regimens are offset by the potential detrimental effects of treatment (16).”
BackgroundGarg, M. B., Lincz, L. F., Adler, K., Scorgie, F. E., Ackland, S. P., & Sakoff, J. A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.421 · Cited by 78 · cited 1×
“The Mayo schedule is widely used for 5-FU administration and the primary toxicities associated with its use include neutropenia (69%), mucositis (58%), and leukopenia (46%) (26).”
BackgroundTsalic, M., Bar‐Sela, G., Beny, A., Visel, B., & Haim, N. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000017526.55135.6d · Cited by 74 · cited 1×
“Female patients have a higher incidence of severe toxicity and death than male patients and the incidence of severe toxicities is more frequent in elderly patients (27).”
BackgroundRuzzo, A., Graziano, F., Galli, F., Galli, F., Rulli, E., Lonardi, S., Ronzoni, M., Massidda, B., Zagonel, V., Pella, N., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.289 · Cited by 71 · cited 1×
“Patients with these SNPs display both increased incidence and more rapid onset of serious neutropenia (57).”
BackgroundMorawska, K., Goirand, F., Marceau, L., Devaux, M., Cueff, A., Bertaut, A., Vincent, J., Bengrine-Lefevre, L., Ghiringhelli, F., & Schmitt, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24338 · Cited by 69 · cited 1×
“004), while patients with at least one AUC below the target during the first 3 cycles displayed significantly reduced progression-free survival (75).”
BackgroundChemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine
Gmeiner, W. H. (2020) · Molecules · doi:10.3390/molecules25153438 · Cited by 66 · cited 2×
“While the anti-cancer activities of FPs result primarily from conversion to FdUMP and inhibition of TS (2,37), up to 90% of 5-FU is degraded (38).”
BackgroundSelf-citationReversal of 5-Fluorouracil-Induced Myelosuppression by Prolonged Administration of High-Dose Uridine
Groeningen, C. J. V., Peters, G. J., Leyva, A., Laurensse, E., & Pinedo, H. M. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.157 · Cited by 64 · cited 1×
“Both leukopenia (78) and 5-FU-induced GI-tract toxicity (79) can be reversed with Uridine treatment.”
BackgroundPallet, N., Hamdane, S., Garinet, S., Blons, H., Zaanan, A., Paillaud, É., Taïeb, J., Laprévôte, O., Loriot, M., & Narjoz, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0962-z · Cited by 59 · cited 1×
“(66) assessed characteristics of 3,680 patients that had completed testing to establish their DPD phenotypes and DPYD genotypes.”
BackgroundHodroj, K., Barthélémy, D., Lega, J., Grenet, G., Gagnieu, M., Walter, T., Guitton, J., & Payen, L. F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100125 · Cited by 57 · cited 1×
“The French cancer institute and French health authority recommend measurement of uracil blood level and implementation of alternative regimens for cancer patients with elevated levels (71).”
BackgroundMurphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J. R., Harvey, H. M., O’Farrell, E., & Bird, B. (2018) · Dose-Response · doi:10.1177/1559325818803042 · Cited by 56
Martens, F. K., Huntjens, D. W., Rigter, T., Bartels, M., Bet, P. M., & Cornel, M. C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01609 · Cited by 51 · cited 1×
“The availability of clear protocols and evidence of their utility were found to be key factors in increasing testing in the Amsterdam University Medical Centers (64).”
BackgroundGmeiner, W. H. (2020) · Cancers · doi:10.3390/cancers12061641 · Cited by 50 · cited 3×
“FPs are central to clinical management of GI-malignancies (3) (e.”
BackgroundSelf-citationPardee, T. S., Gomes, E., Jennings‐Gee, J. E., Caudell, D. L., & Gmeiner, W. H. (2012) · Blood · doi:10.1182/blood-2011-06-362442 · Cited by 47
Self-citationZhou, Y., Dagli-Hernandez, C., & Lauschke, V. M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01084-0 · Cited by 44 · cited 2×
“DPYD polymorphisms with clinical impact—Deficiencies in DPD activity is causative of increased risk for severe toxicity following FP treatment, with 60–80% of DPDdeficient individuals experiencing dose-limiting and potentially life-threatening toxicities, while the corresponding incidence in DPD-proficient patients is…”
BackgroundDelea, T. E., Vera‐Llonch, M., Edelsberg, J., McGarry, L. J., Anton, S., Yood, M. U., & Oster, G. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51083.x · Cited by 36 · cited 1×
“Further, the cost of managing toxicities that result from 5-FU treatment is substantial, with one study finding that the expected cost of hospitalization related to 5-FU toxicity was $3,674 per patient, approximately $2,700 higher among 5-FU patients than patients not treated with 5-FU (36).”
BackgroundSaif, M. W., & Diasio, R. B. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3063-1 · Cited by 35 · cited 1×
“The serious toxicities associated with 5-FU overtreatment can be reversed by treatment with uridine triacetate (77), which increases UTP pools and competes with FUTP for RNA incorporation.”
BackgroundGokare, P. R., Finnberg, N. K., Abbosh, P. H., Dai, J., Murphy, M. E., & El‐Deiry, W. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09859-x · Cited by 33 · cited 2×
“Also p53 repressively regulates DPYD expression (45).”
BackgroundDihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
Fidai, S. S., Sharma, A. E., Johnson, D. N., Segal, J. P., & Lastra, R. R. (2018) · Autopsy and Case Reports · doi:10.4322/acr.2018.049 · Cited by 33 · cited 10×
“Further, it is important to note that the prevalence of DPYD SNPs associated with DPD deficiency and severe FP toxicity varies considerably in different patient populations.”
InfluentialBiochemical rationale for the synergism of 5-fluorouracil and folinic acid.
Moran, R. G., & Keyomarsi, K. (1987) · PubMed · Cited by 26
Neto, O. J. V., Raymundo, S., Franzoi, M. A., Artmann, A. D. C., Tegner, M., Müller, V. V., Hahn, R. Z., Alves, G. V., Schwartsmann, G., Linden, R., et al. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.04.001 · Cited by 25 · cited 1×
“Both fresh saliva and dried saliva spots were shown to display prognostic value (69).”
BackgroundGmeiner, W. H., Tomé, C. M. L., Gibo, D. M., Jennings‐Gee, J. E., Milligan, C., & Debinski, W. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1321-1 · Cited by 24
Self-citationPardee, T. S., Stadelman, K. M., Jennings‐Gee, J. E., Caudell, D. L., & Gmeiner, W. H. (2014) · Oncotarget · doi:10.18632/oncotarget.1937 · Cited by 23
Self-citationLy, R. C., Schmidt, R. E., Kiel, P. J., Pratt, V. M., Schneider, B. P., Radovich, M., Offer, S. M., Diasio, R. B., & Skaar, T. C. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00067 · Cited by 23
Haber, A. O., Jain, A., Mani, C., Nevler, A., Agostini, L. C., Golan, T., Palle, K., Yeo, C. J., Gmeiner, W. H., & Brody, J. R. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0985 · Cited by 23 · cited 1×
“An alternative approach to reducing 5-FU’s RNA-mediated effects and this its systemic toxicities while increasing levels of FdUMP responsible for anti-tumor activity is use of fluoropyrimidine polymers (80,81).”
BackgroundSelf-citation13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
Cunha-Junior, G. F., Marco, L. A. D., Bastos‐Rodrigues, L., Bolina, M. B., Martins, F. L., Pianetti, G. A., César, I. C., & Coelho, L. G. V. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2309-4 · Cited by 22
Automatic quantification of uracil and dihydrouracil in plasma
Robin, T., Saint‐Marcoux, F., Toinon, D., Tafzi, N., Marquet, P., & Balkhi, S. E. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122038 · Cited by 22 · cited 1×
“developed a LC-MS method with an automated sample preparation system that may enable widespread implementation of pre-treatment testing for DPD functional activity (68).”
MethodPalles, C., Fotheringham, S. A., Chegwidden, L., Lucas, M., Kerr, R. S., Mozolowski, G., Rosmarin, D., Taylor, J. C., Tomlinson, I. P. M., & Kerr, D. J. (2021) · Cancers · doi:10.3390/cancers13071497 · Cited by 22
Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
Jee, S. H., Moon, S. M., Shin, U. S., Yang, H. M., & Hwang, D. (2011) · Journal of the Korean Society of Coloproctology · doi:10.3393/jksc.2011.27.6.322 · Cited by 21 · cited 1×
“, T4 stage, poorly-differentiated tumors), the benefits of FP chemotherapy for risk reduction are considered by many oncologists to outweigh potential harmful effects due to treatment (14), and adjuvant chemotherapy, frequently FP doublet (5-FU/LV) may be administered (15).”
BackgroundGmeiner, W. H., Dominijanni, A., Haber, A. O., Ghiraldeli, L. P., Caudell, D. L., D’Agostino, R., Pasche, B. C., Smith, T. L., Deng, Z., Kiren, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0516 · Cited by 21 · cited 2×
“, CF10) in preclinical models (82–84), and demonstrated these result in sustained high plasma levels of FdU and FdUMP while not causing serious systemic toxicities that occur with 5-FU treatment, in part due to reduced dependence on DPD-mediated degradation (80).”
BackgroundSelf-citationA review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
Deac, A. L., Burz, C. C., Bocse, H., Bocșan, I. C., & Buzoianu, A. D. (2020) · Medicine and Pharmacy Reports · doi:10.15386/mpr-1564 · Cited by 20
Lunenburg, C. A. T. C., Henricks, L. M., Kuilenburg, A. B. P., Mathijssen, R. H. J., Schellens, J. H. M., Gelderblom, H. A. J., Guchelaar, H., & Swen, J. J. (2018) · Genes · doi:10.3390/genes9120585 · Cited by 19
Maharjan, A. S., McMillin, G. A., Patel, G. K., Awan, S., Taylor, W. R., Pai, S. G., Frankel, A. E., Nelson, C. L., Wang, B., Hosein, P. J., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.04.005 · Cited by 18 · cited 1×
“A preliminary study indicated *9A was associated with increased risk for serious toxicities, however a later study with larger sample did not reproduce the earlier trend (61).”
ResultPark, H., Jin, R. U., Wang‐Gillam, A., Suresh, R., Rigden, C. E., Amin, M. A., Tan, B. R., Pedersen, K. S., Lim, K., Trikalinos, N. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2020 · Cited by 18 · cited 1×
“option for adjuvant chemotherapy of pancreatic cancer (23), and to be an effective option in patients with advanced gastroesophageal adenocarcinoma (24).”
BackgroundGmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
Self-citationLeung, H. W. C., & Chan, A. L. F. (2015) · Biomedical Reports · doi:10.3892/br.2015.513 · Cited by 16 · cited 1×
“Deficiencies in DPD activity occur in an estimated 3–8% of patients (34,41), and certain populations such as individuals of African descent, are at especially high risk to drug-induced toxicities due to variability in drug metabolism (42) while in Asian populations a distinct spectrum of polymorphisms affecting DPD ac…”
BackgroundJf, S., Cano, J. P., Jp, R., Aubert, C., & Carcassonne, Y. (1983) · PubMed · Cited by 16
Öhrling, K., Karlberg, M., Edler, D., Hallström, M., & Ragnhammar, P. (2012) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2012.11.003 · Cited by 10 · cited 1×
“The mechanistic basis for lack of efficacy of FPs in dMMR CRC is not clearly understood, however MSI is also associated with elevated thymidylate synthase (TS) (20,21), which is the molecular target of FP chemotherapy (2).”
BackgroundKumagai, A., Iijima, S., 孝之, 野., Furuya, I., Ohashi, Y., Tsunoda, K., Onodera, K., Tsunoda, N., Komatsu, Y., & Hirano, T. (2018) · BDJ Open · doi:10.1038/s41405-018-0008-2 · Cited by 9 · cited 1×
“, colorectal, gastric, pancreatic) and are widely used to treat head-and-neck cancer (31), basal cell carcinoma (32), and other malignancies.”
BackgroundSaif, M. W., Hachem, H., Purvey, S., Hamal, R., Zhang, L., Siddiqui, N. S., Godara, A., & Diasio, R. B. (2020) · Archives of Pharmacology and Therapeutics · doi:10.33696/pharmacol.2.012 · Cited by 7 · cited 1×
“Polymorphisms in TYMS, which encodes thymidylate synthase (TS), the principal target of 5-FU are also implicated in 5-FU toxicity and combined DPYD and TYMS genotyping could identify a majority of patients at elevated risk for adverse events (46).”
BackgroundAdenis, A., Mazard, T., Fraisse, J., Chalbos, P., Pastor, B., Evesque, L., Ghiringhelli, F., Mollévi, C., Delaine, S. C., & Ychou, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08312-7 · Cited by 5 · cited 1×
“For highly aggressive mCRC, as occurs with BRAF mutations, four component FP-based regimens FOLFOXIRI and FOLFIRINOX are used (22).”
MethodIkediobi, O. N. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.5542 · Cited by 1 · cited 1×
“, colorectal, gastric, pancreatic) and are widely used to treat head-and-neck cancer (31), basal cell carcinoma (32), and other malignancies.”
Background
Cited by
Gmeiner, W. H., & Okechukwu, C. C. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.136 · Cited by 125
Self-citationRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Adjuvant chemotherapy is administered to reduce the risk for disease recurrence in CRC patients undergoing surgical resection for primary colon cancer with curative intent [131].”
BackgroundSelf-citationResponse to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy
Hertz, D. L., Smith, D. M., Scott, S. A., Patel, J. N., & Hicks, J. K. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2978 · Cited by 35
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice
Ho, T. T., Smith, D. M., Aquilante, C. L., Cicali, E. J., Rouby, N. M. E., Hertz, D. L., Imanirad, I., Patel, J. N., Scott, S. A., Swain, S. M., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3567 · Cited by 33
Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity
Trepka, K. R., Kidder, W. A., Kyaw, T. S., Halsey, T. M., Olson, C. A., Ortega, E. F., Noecker, C. A., Upadhyay, V., Stanfield, D., Steiding, P., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq8870 · Cited by 30
Metadata
- Authors
- Gmeiner, W. H.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Gmeiner, William H.
- ORCID
- Gmeiner, William H.
- Venue
- Precision Cancer Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-12
- Volume
- 4
- Pages
- 38-38
- ISSN
- 2617-2216 (ISSN-L)
- PMC
- PMC8664072
- OpenAlex
- W3190206309
- Cited by
- 25
- References
- 81
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 4
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Precision Cancer Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Cancer Institute (R21CA218933, P30CA012197)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- fluoropyrimidine toxicity, 5-fluorouracil, DPYD polymorphisms, pharmacogenomics, personalized treatment, neutropenia, colorectal cancer, genetic screening, miR-27a, pyrimidine catabolism, therapeutic drug monitoring, pharmacokinetic dosing, area under the curve, thymidylate synthase, p53, gastrointestinal toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.